Samsung Biologics Strikes $353 Million Deal with Belgium's UCB

UCB

BE0003739530

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

Pharmaceuticals

Calendar

18/06/2024 - Citi European Healthcare Conference

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

UCB : UCB all set to reach new highs

March 08, 2024 at 04:10 pm

More Strategies

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

137.2 EUR

Average target price

135 EUR

Spread / Average Target

-1.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
UCB	+73.76%	27.92B
CSL LIMITED	+2.52%	92.1B
SAMSUNG BIOLOGICS CO.,LTD.	-3.16%	37.92B
BIOGEN INC.	-12.49%	32.97B
BIOMARIN PHARMACEUTICAL INC.	-11.82%	16.14B
INCYTE CORPORATION	-0.16%	14.1B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.18%	11.66B
ALTEOGEN INC.	+171.57%	10.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.45%	9.99B
SWEDISH ORPHAN BIOVITRUM AB	+1.12%	8.75B

Biopharmaceuticals

Real-time Euronext Bruxelles Other stock markets 12:15:26 18/06/2024 BST			5-day change	1st Jan Change
137.1 ^EUR	-0.07%		+4.34%	+73.76%

06-13	UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels	CI
06-12	UCB to Share First Presentations of BIMZELX®? (bimekizumab-bkzx) Two-Year Data in Axial Spondyloarthritis and Psoriatic Arthritis at EULAR 2024	CI

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels	06-13	CI
UCB to Share First Presentations of BIMZELX®? (bimekizumab-bkzx) Two-Year Data in Axial Spondyloarthritis and Psoriatic Arthritis at EULAR 2024	06-12	CI
European shares steady after French political tremors, eyes on Fed	06-11	RE
Berenberg Reiterates UCB's Purchase Rating, Raises PT	04-11	MT
UCB : Berenberg, Buy, raises its price target	04-11	CF
UCB: new indication in sight for Bimzelx in the USA	04-04	CF
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx	04-04	CI
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies	03-08	CI
UCB : UCB all set to reach new highs	03-08
UCB Secures British Regulatory Nod for Generalized Myasthenia Gravis Treatment	03-07	MT
South Korean Shares Close Higher After US Fed Chief Hints at Rate Cuts; Samsung Biologics Adds 1%	03-07	MT
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB	03-07	MT
IMIDomics SL announced that it has received funding from UCB SA	03-03	CI
Global markets live: Reckitt, Apple, Warner, Eli Llily, Intel...	02-28
UCB : H2 beat; the prospects remain encouraging	02-28
UCB SA Provides Earnings Guidance for the Year 2025	02-28	CI
Transcript : UCB SA, 2023 Earnings Call, Feb 28, 2024	02-28
UCB SA Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
ZILBRYSQ® Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis in Adult Patients Who Are Anti-Acetylcholine Receptor Antibody Positive	01-03	CI
Drugmakers set to raise U.S. prices on at least 500 drugs in January	12-29	RE
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society Annual Meeting	12-02	CI
Strides Pharma Science Arm Gets US FDA's Nod for Generic Seizure Treatment	11-21	MT
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	11-14	CI
UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor	11-11	CI
UCB Presents New Five-Year Data on Bimzelx® (Bimekizumab-Bkzx) in Ankylosing Spondylitis	11-10	CI

UCB

Equities

UCB